Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study)

Transfusion

Volumn 36, Issue 2, 1996, Pages 155-159

  Wurnig, C ^a   Windhager, R ^a   Schwameis, E ^a   Kotz, R ^a   Zoubek, A ^b   Stockenhuber, F ^a   Kurz, R W ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

^c DANUBE HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; RECOMBINANT ERYTHROPOIETIN; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; BONE TUMOR; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 0030030469     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1996.36296181929.x     Document Type: Article

References (37)

1. Wylie BR. Transfusion transmitted infection: viral and exotic diseases. Anaesth Intensive Care 1993;21:24-30.
2. AuBuchon JP, Dodd RY. Inactivation of microbial contaminants of blood components. Clin Lab Med 1992;12:787-803.
3. Lindholm A. Epidemiology of viral infections in the Swedish blood-donor population. Blood Coagul Fibrinolysis 1994;5(Suppl 3):S13-7.
4. Blumberg N, Chuang-Stein C, Heal JM. The relationship of blood transfusion, tumor staging, and cancer recurrence. Transfusion 1990;30:291-4.
5. Kleinman S, Secord K. Risk of human immunodeficiency virus (HIV) transmission by anti-HIV negative blood - estimates using the lookback methodology. Transfusion 1988;28:499-501.
6. Case DC Jr, Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993;85:801-6.
7. Erslev AJ. Erythropoietin. N Engl J Med 1991;324:1339-44.
8. Zappacosta AR, Perras ST, Bell A. Weekly subcutaneous recombinant human erythropoietin corrects anemia of progressive renal failure. Am J Med 1991;91:229-32.
9. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and phase II clinical trial. N Engl J Med 1987;316:73-8.
10. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992-1000.
11. Eschbach JW, Kelly MR, Haley NR, et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989;321:158-63.
12. Pincus T, Olsen NJ, Russell IJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990;89:161-8.
13. Groopman JE, Feder D. Hematopoietic growth factors in AIDS. Semin Oncol 1992;19:408-14.
14. Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-9.
15. Abels RI. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 1992:87(Suppl 1):4-11.
16. Gamucci T, Thorel MF, Frasca AM, et al. Antianemic activity of erythropoietin in cisplatin-treated patients: a randomized trial (abstract). Presented at the 28th Annual Meeting, May 17-19, 1992, San Diego, CA. Proc Am Soc Clin Oncol 1992;11:408.
17. Markman M, Reichman B, Hakes T, et al. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecol Oncol 1993;49:172-6.
18. Oster W, Herrmann F, Gamm H, et al. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 1990;8:956-62.
19. Platanias LC, Miller CB, Mick R, et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 1991;9:2021-6.
20. Miller CB, Platanias LC, Mills SR, et al. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 1992;84:98-103.
21. Wurnig C, Windhager R, Schwammeis E, Kotz R. Report on a prospective study in recombinant erythropoietin supplement therapy during chemotherapy in patients with malignant bone tumors (abstract). Transfusion 1993;33(Suppl):75S.
22. Jürgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 1988;61:23-32.
23. Winkler K, Bielack S, Delling G, et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (Study COSS-86). Cancer 1990;66:1703-10.
24. Thatcher N. Controlled study of the efficacy and safety of recombinant human erythropoietin (Epoetin alfa; Cilag) in the prevention of anaemia in patients with small cell lung cancer receiving chemotherapy (abstract). Presented at the 19th Congress of the European Society for Medical Oncology, November 18-22, 1994, Lisbon, Portugal. Ann Oncol 1994;5(Suppl 8):89.
25. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 1994;21:21-8.
26. Casati S, Passerini P, Campise MR, et al. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J (Clin Res Ed) 1987;295:1017-20.
27. Windhager R, Millesi H, Kotz R. Resection-replantation for primary malignant tumours of the arm. An alternative to fore-quarter amputation. J Bone Joint Surg Br 1995;77:176-84.
28. James RD, Wilkinson PM, Belli F, et al. Recombinant human erythropoietin in patients with ovarian carcinoma and anemia secondary to cisplatin and carboplatin chemotherapy: preliminary results. Acta Haematol 1992;87(Suppl 1):12-5.
29. Van der Poel CL, Reesink HW, Schaasberg W, et al. Infectivity of blood seropositive for hepatitis C virus antibodies. Lancet 1990;335:558-60.
30. Triulzi DJ, Blumberg N, Heal JM. Association of transfusion with postoperative bacterial infection. Crit Rev Clin Lab Sci 1990;28:95-107.
31. Blajchman MA, Bardossy L, Carmen R, et al. Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. Blood 1993;81:1880-2.
32. Busch OR, Marquet RL, Hop WC, Jeekel J. Colorectal cancer recurrence and perioperative blood transfusions: a critical reappraisal. Semin Surg Oncol 1994;10:195-9.
33. Heslet L, Lybecker H, Andersen PI. [Rational hemotherapy. Indications, complications and practical performance] (Eng abstract). Ugeskr Laeger 1990;152:2635-9.
34. Burrows L, Tartter P. Effect of blood transfusions on colonic malignancy recurrence rate (letter). Lancet 1982;2:662.
35. Blumberg N, Heal JM, Murphy F, et al. Association between transfusion of whole blood and recurrence of cancer. Br Med J 1986;293:530-3.
36. Shirwadkar S, Blajchman MA, Frame B, et al. Effect of blood transfusions on experimental pulmonary metastases in mice. Transfusion 1990;30:188-90.
37. Shirwadkar S, Blajchman MA, Frame B, Singal DP. Effect of allogeneic blood transfusion on solid tumor growth and pulmonary metastases in mice. J Cancer Res Clin Oncol 1992;118:176-80.